Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0UEMEY
ADC Name	scFv(Herceptin)-PE-STXA
Synonyms	scFv (Herceptin) PE STXA Click to Show/Hide
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
	3D MOL	2D MOL
Antibody Name	Trastuzumab scFv		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	PE15-Stx 2a		Payload Info
Therapeutic Target	Eukaryotic elongation factor 2 (EEF2)		Target Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	21.25	ug/mL	SK-BR-3 cells	Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	100	ug/mL	MCF-7 cells	Invasive breast carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21.25 ug/mL	Positive HER2 expression (HER2 +++/++)
Method Description	The cytotoxic effect of recombinant proteins was evaluated by the MTT assay using SKBR-3 and MCF-7 cells.
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	100.00 ug/mL	Low HER2 expression (HER2 -)
Method Description	The cytotoxic effect of recombinant proteins was evaluated by the MTT assay using SKBR-3 and MCF-7 cells.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031

References

Ref 1	Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins. J Steroid Biochem Mol Biol. 2020 Jun;200:105651. doi: 10.1016/j.jsbmb.2020.105651. Epub 2020 Mar 5.